Who Paid My Doc
Daniela Carlos Pons
Urogynecology and Reconstructive Pelvic Surgery Guaynabo, PR Medical Doctor
NPI 1043537145 CMS profile 1397937
101 Ave San Patricio, Ste 1090, Guaynabo, PR 00968
General payments
$1,947
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Daniela Carlos Pons of Guaynabo, PR is reported in the CMS Open Payments database as having received $1,947 across 34 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 36th percentile of Urogynecology and Reconstructive Pelvic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $83 | 1 | |
| 2024 | General | $160 | 1 | |
| 2023 | General | $404 | 4 | |
| 2022 | General | $232 | 4 | |
| 2021 | General | $265 | 4 | |
| 2020 | General | $152 | 4 | |
| 2019 | General | $651 | 16 |
Beside peers
- Daniela Carlos Pons
- Urogynecology and Reconstructive Pelvic Surgery median
- Middle half of Urogynecology and Reconstructive Pelvic Surgery
- National median
In program year 2025, general payments to Daniela Carlos Pons were reported at $83. Among 802 Urogynecology and Reconstructive Pelvic Surgery profiles paid that year, the median was $412 and the middle half received between $133 and $1,300.
Show as a table
| Year | Daniela Carlos Pons | Urogynecology and Reconstructive Pelvic Surgery median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $651 | $358 | $132–$1,270 | $163 |
| 2020 | $152 | $198 | $86–$642 | $114 |
| 2021 | $265 | $361 | $118–$1,182 | $132 |
| 2022 | $232 | $410 | $128–$1,175 | $149 |
| 2023 | $404 | $434 | $152–$1,344 | $160 |
| 2024 | $160 | $494 | $193–$1,331 | $164 |
| 2025 | $83 | $412 | $133–$1,300 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 25 drugsPart D claims
2,562
Drug cost
$425,711
Branded share of claims
51.3%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Myrbetriq Mirabegron | Brand | 566 | $272,254 | |
| Estradiol | Generic | 803 | $68,855 | |
| Premarin Estrogens, Conjugated | Brand | 71 | $31,448 | |
| Tolterodine Tartrate Er Tolterodine Tartrate | Brand | 187 | $13,192 | |
| Trospium Chloride Er Trospium Chloride | Brand | 96 | $11,526 | |
| Gemtesa Vibegron | Brand | 15 | $7,436 | |
| Methenamine Hippurate | Generic | 152 | $6,705 | |
| Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst | Brand | 150 | $3,339 | |
| Nitrofurantoin Nitrofurantoin Macrocrystal | Brand | 54 | $2,293 | |
| Fosfomycin Tromethamine | Generic | 17 | $1,958 |
The 10 drugs with the highest cost, of 25 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 26 billing codesPaid by Medicare
$32,957
Medicare patients
99
Services billed
694
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Diabetes | 68% | |
| Arthritis | 56% | |
| Osteoporosis | 32% | |
| Chronic kidney disease | 27% | |
| Ischemic heart disease | 23% | |
| Depression | 16% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
34 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Urogynecology and Reconstructive Pelvic Surgery in Puerto Rico
Miguel Vazquez Guzman
Urogynecology and Reconstructive Pelvic Surgery · Hato Rey, PR
Shayan Khorsandi
Urogynecology and Reconstructive Pelvic Surgery · Vega Baja, PR
Darlene Vargas Maldonado
Urogynecology and Reconstructive Pelvic Surgery · San Juan, PR
Jimmy Julia-Martinez
Urogynecology and Reconstructive Pelvic Surgery · Guaynabo, PR
Fidel Santos Santos
Urogynecology and Reconstructive Pelvic Surgery · San Juan, PR
Related records
Urogynecology and Reconstructive Pelvic Surgery in Puerto Rico
Practitioners in the same specialty and state, ranked by reported value.
All Urogynecology and Reconstructive Pelvic Surgery
Everyone recorded under this specialty, nationwide.
Doctors in Puerto Rico
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.